Crucell
From Wikipedia, the free encyclopedia
| Crucell N.V. | |
 |
|
| Type | Public |
|---|---|
| Founded | ???? |
| Headquarters | Leiden, The Netherlands |
| Key people | Ronald Brus, President & CEO |
| Industry | Biotechnology |
| Products | Hepavax-Gene, Epaxal, Vivotif, Inflexal |
| Revenue | 28.1 million USD |
| Employees | 900 |
| Website | crucell.com |
Crucell, NASDAQ: CRXL, Euronext: CRXL is a biotechnology company specializing in vaccines and antibodies. Its headquarters are located in Leiden, The Netherlands. Crucell shares are listed on the Euronext Amsterdam exchange and are part of the AMX index.
[edit] History
In 1993 Introgene was founded, which is Crucell’s predecessor. The company forms a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquires U-Bisys to form Crucell.
[edit] External links
| AMX companies of the Netherlands |
|---|
| Aalberts Industries • ASM International • Koninklijke BAM Groep • Boskalis • Corio • Corus Group • Crucell • CSM • Fugro • Heijmans • Hunter Douglas • LogicaCMG • Nutreco • Océ • Ordina • Pharming Group • Randstad Holding • Stork • Univar • USG People • Van der Moolen • VastNed Retail • Vopak • Wereldhave • Wessanen |
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
